UNITED THERAPEUTICS Corp financial data

Symbol
UTHR on Nasdaq
Location
1000 Spring St, Silver Spring, MD
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 598 % +39.7%
Quick Ratio 26.4 % +72.8%
Debt-to-equity 12.4 % -34.6%
Return On Equity 18.8 % -2.03%
Return On Assets 16.8 % +3.71%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.1M shares -3.56%
Common Stock, Shares, Outstanding 42.9M shares -3.84%
Entity Public Float 12.2B USD +33%
Common Stock, Value, Issued 800K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 43.8M shares -1.79%
Weighted Average Number of Shares Outstanding, Diluted 47.3M shares -2.27%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.13B USD +13.5%
Research and Development Expense 544M USD +9.17%
Costs and Expenses 1.63B USD +10.7%
Operating Income (Loss) 1.49B USD +16.7%
Nonoperating Income (Expense) 173M USD +9.09%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.67B USD +15.9%
Income Tax Expense (Benefit) 395M USD +20.7%
Net Income (Loss) Attributable to Parent 1.27B USD +14.5%
Earnings Per Share, Basic 28 USD/shares +17.2%
Earnings Per Share, Diluted 26 USD/shares +16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.34B USD -13.8%
Marketable Securities, Current 1.43B USD -19.5%
Accounts Receivable, after Allowance for Credit Loss, Current 298M USD -12.9%
Inventory, Net 177M USD +20.3%
Other Assets, Current 252M USD +36%
Assets, Current 3.49B USD -12.7%
Deferred Income Tax Assets, Net 355M USD -9.21%
Property, Plant and Equipment, Net 1.56B USD +34.5%
Goodwill 32.3M USD -4.15%
Other Assets, Noncurrent 263M USD +43%
Assets 7.35B USD +3.2%
Accounts Payable, Current 6M USD +7.14%
Employee-related Liabilities, Current 94.2M USD +29.2%
Accrued Liabilities, Current 339M USD +15.8%
Liabilities, Current 546M USD -37.5%
Other Liabilities, Noncurrent 215M USD +44.2%
Liabilities 761M USD -25.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 100K USD -98.6%
Retained Earnings (Accumulated Deficit) 8.19B USD +18.4%
Stockholders' Equity Attributable to Parent 6.59B USD +8.02%
Liabilities and Equity 7.35B USD +3.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 461M USD +22.5%
Net Cash Provided by (Used in) Financing Activities -93.8M USD +91.2%
Net Cash Provided by (Used in) Investing Activities -165M USD -122%
Common Stock, Shares Authorized 245M shares 0%
Common Stock, Shares, Issued 75.7M shares +1.24%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 203M USD +363%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.34B USD -13.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.4M USD -57.1%
Deferred Tax Assets, Valuation Allowance 30.1M USD -2.27%
Deferred Tax Assets, Gross 563M USD +18.8%
Depreciation 19.6M USD +32.4%
Payments to Acquire Property, Plant, and Equipment 74.9M USD +96.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.26B USD +8.81%
Lessee, Operating Lease, Liability, to be Paid 38.6M USD +17.7%
Property, Plant and Equipment, Gross 2.1B USD +28.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6M USD +39.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.1M USD +29.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.1M USD +45.2%
Deferred Tax Assets, Operating Loss Carryforwards 19.8M USD -7.48%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 19.6M USD -18.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.8M USD +38.1%
Depreciation, Depletion and Amortization 19.8M USD +32%
Deferred Tax Assets, Net of Valuation Allowance 533M USD +20.2%
Share-based Payment Arrangement, Expense 136M USD +1.57%
Interest Expense 58.8M USD +41.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%